161 related articles for article (PubMed ID: 16050796)
21. Glutathione transferases as targets for cancer therapy.
Ruzza P; Rosato A; Rossi CR; Floreani M; Quintieri L
Anticancer Agents Med Chem; 2009 Sep; 9(7):763-77. PubMed ID: 19538171
[TBL] [Abstract][Full Text] [Related]
22. Glutathione-S-transferase selective release of metformin from its sulfonamide prodrug.
Rautio J; Vernerová M; Aufderhaar I; Huttunen KM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5034-6. PubMed ID: 25248681
[TBL] [Abstract][Full Text] [Related]
23. A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides.
Hamilton DS; Kavarana MJ; Sharkey EM; Eiseman JL; Creighton DJ
J Med Chem; 1999 May; 42(10):1823-7. PubMed ID: 10346934
[TBL] [Abstract][Full Text] [Related]
24. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I
Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340
[TBL] [Abstract][Full Text] [Related]
25. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
Denny WA; Wilson WR
J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
[TBL] [Abstract][Full Text] [Related]
26. New-generation platinum drugs in the treatment of cisplatin-resistant cancers.
McKeage MJ
Expert Opin Investig Drugs; 2005 Aug; 14(8):1033-46. PubMed ID: 16050795
[TBL] [Abstract][Full Text] [Related]
27. [Anti-cancer drug resistance and glutathione S-transferases].
Sato K; Tsuchida S; Tamai K
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):592-8. PubMed ID: 2650631
[TBL] [Abstract][Full Text] [Related]
28. Glutathione-S-transferase-pi expression regulates sensitivity to glutathione-doxorubicin conjugate.
Tashiro K; Asakura T; Fujiwara C; Ohkawa K; Ishibashi Y
Anticancer Drugs; 2001 Sep; 12(8):707-12. PubMed ID: 11604559
[TBL] [Abstract][Full Text] [Related]
29. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
30. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
31. Glutathione transferases and development of new principles to overcome drug resistance.
Sau A; Pellizzari Tregno F; Valentino F; Federici G; Caccuri AM
Arch Biochem Biophys; 2010 Aug; 500(2):116-22. PubMed ID: 20494652
[TBL] [Abstract][Full Text] [Related]
32. Mammalian glutathione S-transferase: regulation of an enzyme system to achieve chemotherapeutic efficacy.
Gulick AM; Fahl WE
Pharmacol Ther; 1995 May; 66(2):237-57. PubMed ID: 7667397
[TBL] [Abstract][Full Text] [Related]
33. 3-Methyleneoxindole: an affinity label of glutathione S-transferase pi which targets tryptophan 38.
Pettigrew NE; Brush EJ; Colman RF
Biochemistry; 2001 Jun; 40(25):7549-58. PubMed ID: 11412109
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibitors of glutathione transferase P1 with trioxane structure as anticancer agents.
Bräutigam M; Teusch N; Schenk T; Sheikh M; Aricioglu RZ; Borowski SH; Neudörfl JM; Baumann U; Griesbeck AG; Pietsch M
ChemMedChem; 2015 Apr; 10(4):629-39. PubMed ID: 25694385
[TBL] [Abstract][Full Text] [Related]
35. Brostallicin: a new concept in minor groove DNA binder development.
Broggini M; Marchini S; Fontana E; Moneta D; Fowst C; Geroni C
Anticancer Drugs; 2004 Jan; 15(1):1-6. PubMed ID: 15090736
[TBL] [Abstract][Full Text] [Related]
36. Structures of class pi glutathione S-transferase from human placenta in complex with substrate, transition-state analogue and inhibitor.
Prade L; Huber R; Manoharan TH; Fahl WE; Reuter W
Structure; 1997 Oct; 5(10):1287-95. PubMed ID: 9351803
[TBL] [Abstract][Full Text] [Related]
37. Isozyme specificity of novel glutathione-S-transferase inhibitors.
Flatgaard JE; Bauer KE; Kauvar LM
Cancer Chemother Pharmacol; 1993; 33(1):63-70. PubMed ID: 8269591
[TBL] [Abstract][Full Text] [Related]
38. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
39. Sulphonamide-based bombesin prodrug analogues for glutathione transferase, useful in targeted cancer chemotherapy.
Axarli I; Labrou NE; Petrou C; Rassias N; Cordopatis P; Clonis YD
Eur J Med Chem; 2009 May; 44(5):2009-16. PubMed ID: 19019494
[TBL] [Abstract][Full Text] [Related]
40. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines?
Campling BG; Baer K; Baker HM; Lam YM; Cole SP
Br J Cancer; 1993 Aug; 68(2):327-35. PubMed ID: 8102244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
